How to make GLP-1 coverage sustainable
Most GLP-1 programs drive up costs. This playbook shows the employer path to sustainable coverage based on one of the largest real-world GLP-1 studies.
Based on leading GLP-1 real-word study
Must-read for benefit leaders
Proven way to make GLP-1 coverage ROI-positive
What's inside
Why most GLP-1 programs are overmedicating (and overspending)
How Embla achieved clinical trial-level outcomes (with less than half the medication)
The difference between fixed-dose vs. treat-to-target GLP-1 prescribing
How outcomes held steady across BMI groups and semaglutide doses
The role behavioral care plays in sustainable weight loss
What this means for benefit design, plan costs, and long-term GLP-1 access
Based on top GLP-1 study showing better outcomes at lower doses
The TRIM study, presented by the Embla research team at ECO 2025, followed 2,694 adults over 64 weeks and found an average weight loss of 16.7% — using less than half the typical semaglutide dose.
Nearly 80% successfully tapered or stopped medication. Results were consistent across BMI groups, dose levels, and demographics, showing what’s possible with a behavior-first, coaching-led model.
A must-read for:
HR and benefits leaders navigating GLP-1 demand and rising claims
Brokers and consultants looking for evidence-based, cost-controlled solutions
Clinical teams exploring sustainable models for medication tapering
Finance leaders focused on long-term cost containment and ROI